4D Molecular Therapeutics, Inc.
FDMT
$4.28
$0.040.94%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.00K | 3.00K | 5.00K | 28.00K | -19.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.00K | 3.00K | 5.00K | 28.00K | -19.00K |
| Cost of Revenue | 43.09M | 38.48M | 31.86M | 27.87M | 26.03M |
| Gross Profit | -43.09M | -38.48M | -31.86M | -27.84M | -26.05M |
| SG&A Expenses | 13.03M | 12.65M | 10.60M | 10.29M | 10.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.12M | 51.14M | 42.46M | 38.16M | 36.63M |
| Operating Income | -56.12M | -51.13M | -42.46M | -38.14M | -36.65M |
| Income Before Tax | -49.67M | -43.84M | -34.95M | -32.40M | -32.28M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.67M | -43.84M | -34.95M | -32.40M | -32.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.67M | -43.84M | -34.95M | -32.40M | -32.28M |
| EBIT | -56.12M | -51.13M | -42.46M | -38.14M | -36.65M |
| EBITDA | -55.02M | -49.94M | -41.26M | -36.96M | -35.55M |
| EPS Basic | -0.89 | -0.79 | -0.63 | -0.66 | -0.75 |
| Normalized Basic EPS | -0.56 | -0.49 | -0.40 | -0.41 | -0.47 |
| EPS Diluted | -0.89 | -0.79 | -0.63 | -0.66 | -0.75 |
| Normalized Diluted EPS | -0.56 | -0.49 | -0.40 | -0.41 | -0.47 |
| Average Basic Shares Outstanding | 55.64M | 55.55M | 55.28M | 49.27M | 42.87M |
| Average Diluted Shares Outstanding | 55.64M | 55.55M | 55.28M | 49.27M | 42.87M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
